RNTX

Rein Therapeutics Inc

NASDAQ: RNTX · HEALTHCARE · BIOTECHNOLOGY

$1.15

+0.00% today

Updated 2026-06-04

Market cap

$78.73M

P/E ratio

—

P/S ratio

—

EPS (TTM)

$-1.90

Dividend yield

—

52W range

$1 – $2

Volume

0.7M

Market cap

$78.73M

P/E ratio

—

P/S ratio

—

EPS (TTM)

$-1.90

Dividend yield

—

52W range

$1 – $2

Volume

0.7M

WallStSmart proprietary scores

out of 100

Grade: F

Strong Sell

Investment rating

4.3

Growth

3.5

Quality

3.0

Profitability

5.0

Valuation

C+

1/9

Piotroski F-Score

Weak

-24.9

Altman Z-Score

Distress

—

Industry rank

—

View all highly rated stocks (75+) →202 stocks currently score above 75

Price targets

Analyst target

$8.00

+595.65%

12-Month target

—

Intrinsic (DCF)

—

Margin of safety

—

0 Strong Buy1 Buy0 Hold0 Sell0 Strong Sell

Price chart

Stock snapshot

Strengths

+ Debt/equity 0.42x — low leverage

Risks

- Piotroski 1/9 — weak financial health

- Altman Z -24.94 — distress zone

- Thin margins at 0.00%

- Negative free cash flow $-3.42M

Key financials

Revenue Net Income Free Cash Flow

Metric	2022	2023	2024	2025	TTM
Revenue	$0.00	$0.00	$0.00	$0.00	$0.00
Net income	$-27329.00	$-15732.00	$-62.88M	$-49.87M	$-5.84M
EPS	—	—	—	—	$-1.90
Free cash flow	$-24.86M	$-19.81M	$-22.29M	$-19.36M	$-3.42M
Profit margin	—	—	—	—	—

Peer comparison

Company	Mkt Cap	Score	Growth	Profit	Value	Quality	MoS	Rating
RNTX	$78.73M	17	4.3	3.0	5.0	3.5	—	Avoid
LLY	$948.95B	78	10.0	10.0	5.0	6.0	—	Strong Buy
JNJ	$536.54B	59	4.7	9.0	3.3	6.0	-71.41%	Buy
ABBV	$380.57B	63	4.0	8.0	4.0	5.0	-55.64%	Buy
UNH	$343.21B	54	5.3	5.5	4.7	5.5	-26.61%	Buy
MRK	$285.64B	50	3.3	8.0	2.7	5.0	-49.34%	Hold

Smart narrative

Rein Therapeutics Inc trades at $1.15. Our Smart Value Score of 17/100 indicates the stock is weak. The company scores 1/9 on the Piotroski F-Score. With an Altman Z-Score of -24.94, it sits in the distress.

Frequently asked questions

What is Rein Therapeutics Inc's stock price?

Rein Therapeutics Inc (RNTX) trades at $1.15.

Is Rein Therapeutics Inc overvalued?

Rein Therapeutics Inc carries a Smart Value Score of 17/100 (Grade F), which we rate Strong Sell. That score blends growth, quality, and valuation into one read.

What is the price target of Rein Therapeutics Inc (RNTX)?

The 12-month analyst consensus target is $8.00, about 595.7% above the current $1.15. A consensus target is the average of Wall Street's 12-month forecasts, so it works as a sentiment gauge rather than a guarantee, and it resets with every earnings cycle.

Altman Z-Score?

Rein Therapeutics Inc's Altman Z-Score is -24.94, which places it in the distress. The Altman Z-Score gauges bankruptcy risk from profitability, leverage, and asset efficiency, and a higher reading points to lower financial distress risk.

Company info

SectorHEALTHCARE

IndustryBIOTECHNOLOGY

CountryUSA

ExchangeNASDAQ

CurrencyUSD

Quick metrics

P/S ratio—

ROE-163.40%

Beta1.35

50D MA$1.29

200D MA$1.29

Shares out0.09B

Float0.07B

Short ratio—

Avg volume0.7M

Performance

1 week—

1 month—

3 months—

YTD—

1 year—

3 years—

5 years—

Compare

RNTX vs LLY →RNTX vs JNJ →RNTX vs ABBV →Stock screener →